Ethical priorities for international collaborative adaptive platform trials for public health emergencies
BMJ Glob Health
.
2023 Jul;8(7):e012930.
doi: 10.1136/bmjgh-2023-012930.
Authors
Katharine Wright
1
,
Joseph Ali
2
,
Alun Davies
3
,
Paul Glasziou
4
,
Nina Gobat
5
,
Tanja Kuchenmüller
6
,
Katherine Littler
7
,
Chelsea Modlin
2
,
Lee-Anne Pascoe
7
,
Andreas Reis
7
,
Jerome Amir Singh
8
Affiliations
1
Consultant, World Health Organization, Geneva, Switzerland katharines.wright@icloud.com.
2
Berman Institute of Bioethics, Johns Hopkins University, Baltimore, Maryland, USA.
3
Nuffield Department of Medicine, University of Oxford, Oxford, UK.
4
Institute for Evidence-Based Healthcare, Bond University, Robina, Queensland, Australia.
5
Community Readiness and Resilience Unit, World Health Organization, Geneva, Switzerland.
6
Evidence to Policy and Impact Unit, World Health Organization, Geneva, Switzerland.
7
Health Ethics and Governance Unit, WHO, Geneva, GE, Switzerland.
8
Howard College School of Law, University of KwaZulu Natal, Durban, South Africa.
PMID:
37524503
PMCID:
PMC10391826
DOI:
10.1136/bmjgh-2023-012930
No abstract available
Keywords:
COVID-19; Health policy; Other study design.
Publication types
Research Support, Non-U.S. Gov't
MeSH terms
Decision Making
Emergencies*
Humans
Public Health*
Grants and funding
WT_/Wellcome Trust/United Kingdom
001/WHO_/World Health Organization/International